Metamizol Kalceks (Metamizole Sodium Monohydrate)

Metamizole reduces pain and fever primarily by inhibiting prostaglandin synthesis through blockade of cyclooxygenase enzymes, which lowers peripheral sensitisation and central pain signalling. The decrease in prostaglandins also affects the hypothalamic thermoregulatory centre, producing an antipyretic effect. The precise molecular target is not fully defined.

The dosage of Metamizol Kalceks is determined by the prescribing clinician based on the patient’s condition, age, weight and clinical response. The prescriber selects the appropriate volume and concentration for intramuscular or intravenous administration, following local guidelines and product labeling.

Safety data for Metamizole in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or used only when the potential benefit outweighs the risk. Healthcare providers should evaluate the individual situation and consider alternative therapies when treating pregnant or nursing patients.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain logistics if needed—and assistance with import documentation.

Compared with traditional non‑steroidal anti‑inflammatory drugs (NSAIDs), Metamizole offers potent analgesic and antipyretic effects with a lower incidence of gastric irritation, but it carries a risk of rare blood dyscrasias such as agranulocytosis. Unlike opioids, it does not cause respiratory depression, making it a useful alternative in certain acute pain scenarios.

Metamizol Kalceks should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. The product must not be frozen or shaken vigorously. Maintain the cold‑chain during transport and keep the vial in its original packaging until use to preserve stability.

The medication is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration is performed by qualified healthcare professionals using aseptic technique. The dose volume is drawn into a syringe, and the injection site is selected according to clinical guidelines, ensuring proper dilution if required.

The most serious adverse reactions include agranulocytosis, severe neutropenia, and life‑threatening allergic responses such as anaphylaxis or Stevens‑Johnson syndrome. These conditions can be fatal if not identified promptly, so regular blood‑count monitoring and immediate medical attention for signs of infection or hypersensitivity are essential.

Metamizole is contraindicated in patients with known hypersensitivity to pyrazolones or any component of the formulation. It should also be avoided in individuals with a history of severe blood dyscrasias, uncontrolled hypertension, or those receiving concurrent myelosuppressive therapy. Clinicians must assess each patient’s medical history before prescribing.